Dive into some
exciting news

SeaStar Medical recognizes that key inflammatory messengers can be transformed. See how we're transforming medicine.

Disruptive thinking from a solutions-oriented organization

SeaStar Medical is a privately held, clinical-stage medical therapeutics company headquartered in Denver, Colorado. Our revolutionary Selective Cytopheretic Device (SCD) is in the final stages of clinical testing with an anticipated launch date in the second half of 2021.

For any media inquiries, please contact patty@pscconsulting.net

Latest News

SeaStar Medical Appoints New Board Chairman To Deliver Growth

DENVER, May 21, 2020 /PRNewswire/ — SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced the appointment of Ray Chow as chairman of its Board of Directors. Ray will lead the Board, working with the existing investors and any future investment groups. In addition, Ray will oversee Business Development and Global Partnership activities for SeaStar Medical. Ray has served as a member of the Board since 2019. He is the principal of Bio-Mondo Consulting, a management consultancy to the biopharmaceutical industry and has deep experience in global product launches, sales expansion and strategic

Read more >

Ohio State Uses Experimental Therapy to Combat Excess Inflammation in COVID-19 Patients

COLUMBUS, Ohio – Researchers at The Ohio State University Wexner Medical Center are the first in Ohio to test a therapy that reduces the uncontrolled inflammation in COVID-19 patients that has been linked to severe respiratory distress, heart inflammation, multi-organ failure and death. Using the SeaStar Medical CLR 2.0 filter, doctors are filtering patient blood to remove immune system proteins called cytokines. The cytokines set off severe inflammation causing the lungs to fill with fluid making it difficult to breathe. Patients can develop acute respiratory distress syndrome, multi-organ failure and myocarditis. “By limiting the cytokines in the blood, we can prevent

Read more >

SeaStar Medical to Initiate a Pilot Study of Selective Cytopheretic Device in COVID-19 patients with Acute Respiratory Distress Syndrome and Acute Kidney Injury

Trial will test clinical activity, safety and efficacy of novel immunomodulating medical device to reverse and repair organ injury. DENVER, April 28, 2020 /PRNewswire/ — SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced it has received approval of their Investigational Device Exemption (IDE) supplement from the U.S. Food and Drug Administration (FDA) to initiate a feasibility, compassionate use study. The immunomodulating medical device, the Selective Cytopheretic Device (SCD), will focus on positive COVID-19 patients with acute respiratory distress syndrome (ARDS) or Acute Kidney Injury (AKI). The IDE supplement approval recognizes there

Read more >

The SCD is an investigational device and is not currently available for sale. Please check back for further updates on device availability in your region.